MedPath

Confronting Cancer as a Community

Recruiting
Conditions
Colorectal Carcinoma
Interventions
Procedure: Archive Sample Retrieval
Procedure: Biospecimen Collection
Other: Electronic Health Record Review
Other: Genetic Testing
Other: Questionnaire Administration
Registration Number
NCT06063928
Lead Sponsor
University of Southern California
Brief Summary

This study aims to better understand the cause of colorectal cancer and how to find the best treatment for Hispanic patients with colorectal cancer. The genetic information in the blood and tissues may explain why patients who have the same type of cancer and receive the same treatment do not always have the same results. By combining genetic (certain qualities or traits passed from parents to offspring) information with clinical data, such as the responses of different kinds of cancers to different treatments, this study could lead to more knowledge about why certain cancers occur and why they respond differently to treatments. Information gathered from this study may help researchers match treatments to the genetics of each patient and the genetic changes in their tumor. This approach is known as personalized medicine.

Detailed Description

PRIMARY OBJECTIVE:

I. To create a well-characterized cohort of Hispanic patients with colon cancer, with patient-level data, genomic, transcriptomic, clinical, and outcomes data.

SECONDARY OBJECTIVES:

I. To identify genomic/transcriptomic predictors of treatment outcomes (time to recurrence, time to progression, and overall survival).

II. To identify associations between somatic tumor deoxyribonucleic acid (DNA) methylation patterns and clinical outcomes.

III. To examine patterns of patient engagement in genetic/genomic testing among Hispanic patients with colorectal cancer (CRC).

IV. To characterize the gut microbiome through a stool collection kit and nucleic acid extraction process.

EXPLORATORY OBJECTIVES:

I. To validate, characterize and discover molecular processes in the CRC tumor common to other CRC populations and specific to Hispanic patients.

II. To determine whether comorbidities are associated with variation in tumor molecular pathways and whether comorbidities are effect modifiers of associations between tumor molecular variation and disease outcomes and response to treatment in Hispanic CRC patients.

OUTLINE: This is an observational study.

Patients undergo blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. Patients also have their medical records reviewed on study.

After return of genetic testing results, patients are followed up at 2 weeks, 12 months, and then annually thereafter.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Self-reported Hispanic ethnicity
  • Diagnosed with colon or rectal cancer (at any time and stage; lifetime diagnosis and in survival are eligible)
  • Has a tumor tissue sample archived or plans to have tissue archived from a standard care procedure
  • Age >= 18 years
Exclusion Criteria
  • Inability to understand and the willingness to sign a written informed consent

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Observational (stool, blood, tissue, genetic testing, questionnaires)Electronic Health Record ReviewPatients undergo stool sample collection, blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. Patients also have their medical records reviewed on study.
Observational (stool, blood, tissue, genetic testing, questionnaires)Genetic TestingPatients undergo stool sample collection, blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. Patients also have their medical records reviewed on study.
Observational (stool, blood, tissue, genetic testing, questionnaires)Questionnaire AdministrationPatients undergo stool sample collection, blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. Patients also have their medical records reviewed on study.
Observational (stool, blood, tissue, genetic testing, questionnaires)Archive Sample RetrievalPatients undergo stool sample collection, blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. Patients also have their medical records reviewed on study.
Observational (stool, blood, tissue, genetic testing, questionnaires)Biospecimen CollectionPatients undergo stool sample collection, blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study. Patients also have their medical records reviewed on study.
Primary Outcome Measures
NameTimeMethod
Overall survival (OS)Assessed up to 6 years

Determined from start of treatment until death due to any cause.

Time to recurrence (TTR)Assessed up to 6 years

Determined from time of registration to date of documented event such as treatment-related deaths, second same or other primary cancers, and deaths from other cancers.

Progression free survival (PFS)Assessed up to 6 years

Determined from start of treatment to time of progression or death (whichever comes first).

Changes in genomic knowledgeBaseline, at 2 weeks, and at 12-month follow up

The KnowGene scale will be used. Score Range = 0-16. Higher score indicates higher knowledge.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Los Angeles County-USC Medical Center

🇺🇸

Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath